Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;90(1069):20160590.
doi: 10.1259/bjr.20160590. Epub 2016 Oct 19.

T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

Nigel Hoggard  1 , Giles H Roditi  2
Affiliations
Review

T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

Nigel Hoggard et al. Br J Radiol. 2017 Jan.

Abstract

There is growing evidence for the accumulation of gadolinium (Gd) in patients administered with intravenous Gd-based contrast agents, even in the absence of renal impairment. This review of the literature will discuss what has been found to date in cadaveric human studies, clinical studies of patients and from animal models. Evidence for the potential route of entry into the brain will be examined. The current state of knowledge of effects of Gd accumulation in the brain is discussed. We will then discuss what the possible implications may be for the choice of Gd-based contrast agents in clinical practice.

PubMed Disclaimer

References

    1. European Medicines Agency. Assessment report for gadolinium-containing contrast agents 2010. In: Proced. No. EMEA/H/A-31/1097. [Accessed 21 April 2016]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/...
    1. Do JG, Kim YB, Lee DG, Hwang JH. A case of delayed onset nephrogenic systemic fibrosis after gadolinium based contrast injection. Ann Rehabil Med 2012; 36: 880–6. doi: https://doi.org/10.5535/arm.2012.36.6.880 - DOI - PMC - PubMed
    1. Thomson LK, Thomson PC, Kingsmore DB, Blessing K, Daly CD, Cowper SE, et al. Diagnosing nephrogenic systemic fibrosis in the post-FDA restriction era. J Magn Reson Imaging 2015; 41: 1268–71. doi: https://doi.org/10.1002/jmri.24664 - DOI - PubMed
    1. Sherry AD, Caravan P, Lenkinski RE. A primer on gadolinium chemistry. J Magn Reson Imaging 2009; 30: 1240–8. doi: https://doi.org/10.1002/jmri.21966 - DOI - PMC - PubMed
    1. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE, et al. Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 2009; 1: 479–88. doi: https://doi.org/10.1039/b905145g - DOI - PubMed